Nikhil Sudhir Sathe | Biological Networks | Best Researcher Award

Published on by Network Science

Dr. Nikhil Sudhir Sathe | Biological Networks | Best Researcher Award

Reliance Life Sciences Pvt Ltd | India

Dr. Nikhil Sudhir Sathe (PhD), currently associated with Laboratory Animal Research Services (LARS), is a distinguished researcher with over 20 years of expertise in drug discovery and preclinical evaluation of new chemical entities. His extensive professional experience encompasses in vitro genotoxicology, cell and microbial culture (aerobic, anaerobic, and viral systems including rabies virus), and small laboratory animal studies. Throughout his career at Reliance Life Sciences, Vimta Labs, Dabur Research Centre, and Wockhardt Research Centre, Dr. Sathe has demonstrated exceptional proficiency in GLP-compliant laboratory practices, including bacterial reverse mutation, chromosomal aberration, micronucleus, ELISA, cytotoxicity, and microbial monitoring assays. His early research contributions involved innovative in vitro models for evaluating the efficacy of antimicrobial and cosmetic products. Academically, he holds a Master’s and Bachelor’s degree in Microbiology from Shivaji University, Kolhapur, both with distinction. Dr. Sathe has contributed significantly to scientific literature with publications in reputed journals such as Vaccine, Microbial Pathogenesis, Infectious Medicine, and BioMed, focusing on bacteriophage therapy and vaccine development against multidrug-resistant pathogens and SARS-CoV-2. His scholarly achievements are complemented by active participation in national conferences and workshops, reflecting his deep commitment to advancing microbiological and biomedical research.

Profiles: Scopus | Orcid | Google Scholar

Featured Publications

"Unveiling Lytic Bacteriophages as Promising Biotherapeutics for the Control of Multidrug-Resistant Pseudomonas aeruginosa", CS Nikhil Sathe, Eugene Athan, Arnab Kapat, BioMed, 2025.

"Safety, immunogenicity and efficacy of Relcovax®, a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus", N Sathe, S Shaikh, M Bhavsar, L Parte, A Gadiparthi, S Kad, S Sensarma, Vaccine, 2024.

"Bacteriophage vB_kpnS-Kpn15: Unveiling its potential triumph against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae-Unraveling efficacy through innovative", N Sathe, C Suphioglu, E Athan, A Kapat, Microbial Pathogenesis, 2024.

"Pseudomonas aeruginosa: Infections and novel approaches to treatment “Knowing the enemy” the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment", N Sathe, P Beech, L Croft, C Suphioglu, A Kapat, E Athan, Infectious medicine 2, 2023.

"Development of a novel therapy using bacteriophages: An alternative to antibiotics", NS Sathe, Deakin University, 2023.

Eman Kamal Ahmed Abdelall | Biological Network | Best Researcher Award

Published on by Network Science

Dr. Eman Kamal Ahmed Abdelall | Biological Network | Best Researcher Award

Beni-Suef University | Egypt

Dr. Eman Kamal Ahmed Abdelall is a distinguished Professor of Pharmaceutical Organic Chemistry at Beni-Suef University, Egypt, with an outstanding academic and research career spanning over three decades. She earned her Ph.D. in Pharmaceutical Organic Chemistry from Cairo University in 2006 and has since advanced through academic ranks to become a full professor in 2018. Dr. Abdelall has held several key administrative positions, including Vice Dean of Student Affairs and Vice Dean for Environmental Affairs, and currently serves as the Head of the Department of Pharmaceutical Organic Chemistry. A prolific researcher, she has published over 53 peer-reviewed papers in leading journals indexed in Scopus and Google Scholar, with notable contributions to anti-inflammatory, anticancer, and antiviral drug design. Her excellence in scientific research has earned her numerous university honors, medals of excellence, and funded research awards. Dr. Abdelall is also an active reviewer for international journals, a member of higher education promotion committees, and a mentor who has supervised multiple Master’s and Doctoral theses, making her a leading figure in Egypt’s pharmaceutical research community.

Profiles: Scopus | Orcid | Google Scholar

Featured Publications

"Molecular docking, ADME study, Cardiovascular biomarkers and gastric safety of new pyrazoles as selective anti-inflammatory agents", EKA Abdelall, SS Zaghlool, JZF Saad, JN Philoppes, Journal of Molecular Structur, 2025.

"Synthesis of new selective agents with dual anti-inflammatory and SARS-CoV-2 Mpro inhibitory activity: Antipyrine-celecoxib hybrid analogues; COX-2, COVID-19 cytokine storm and replication inhibitory activities", EKA Abdelall, HAH Elshemy, MB Labib, JN Philoppes, FEM Ali, Bioorganic Chemistry, 2025.

"Synthesis and in silico studies of Novel thiophene–celecoxib hybrid with excellent cardiotoxicity and nephrotoxicity safety profiles", EKA Abdelall, PF Lamie, MB Labib, M El-Daly, A Mishrif, European Journal of Medicinal Chemistry, 2025.

"Novel quinoxaline derivatives as promising cytotoxic agents: structure-based design, in silico studies, VEGFR-2 inhibition, and PI3K/AKT/mTOR pathway modulation", EKA Abdelall, HAH Elshemy, H Abdelmegeed, N Ryad, AA Abdelaziz, Bioorganic Chemistr, 2025.

"The Role of Clinical Pharmacist in Monitoring Drug Therapy in the Cardiovascular and Coronary Care Units in Libya", ASH Alhomri, AA Battah, AA Elberry, EKA Abdelall, R Hussein", Pharmacy Practice, 2024.

Xiaosuo Wang | Technological Networks | Best Researcher Award

Published on by Network Science

Dr. Xiaosuo Wang | Technological Networks | Best Researcher Award

The University of Sydney | Australia

Dr. Xiaosuo Wang is a distinguished researcher specializing in mass spectrometry, metabolomics, lipidomics, and proteomics, with deep expertise in vascular biology and heart failure. She earned her PhD in Medicine from the University of Sydney in 2009, focusing on novel ELISA methods to detect oxidised apolipoproteins in cardiovascular disease, following a master’s degree in Physiology and Pharmacology from the University of New South Wales and a bachelor’s in Biomedical Engineering from the Fourth Military Medical University, China. Currently a Senior Research Fellow and Senior Lecturer at the University of Sydney’s Charles Perkins Centre, she leads pioneering projects in biomarker discovery, metabolic assays, and multi-omics platform development for applications in liver disease, heart failure, and population health. Her work integrates advanced mass spectrometry, lipidomics, and metabolomics workflows with translational innovations such as point-of-care assays and biosensor development. Previously, as a Metabolomics Research Scientist at the Victor Chang Cardiac Research Institute and Manager of the Bosch Mass Spectrometry Facility, she developed over 60 advanced LC-MS assays and supported a wide range of biological and clinical research. Dr. Wang’s prolific contributions include more than 40 peer-reviewed publications, numerous conference presentations, and significant advancements in analytical methodologies for precision medicine.

Profiles: Scopus | Orcid ID

Featured Publications

"Rapid On-Demand Point-of-Care Monitoring of Clozapine and Its Metabolite Norclozapine Using Miniature Mass Spectrometry. Pharmaceuticals, Xiaosuo Wang; Wei Yi Lew; Yang Yang; Nan Zhang; Jiexun Bu; Zhentao Li; Michael Fitzpatrick; Paul Bonnitcha; David Sullivan; Wenpeng Zhang et al., 2025"

"The Heart Has Intrinsic Ketogenic Capacity that Mediates NAD + Therapy in HFpEF, Circulation Research, Yen Chin Koay; Bailey McIntosh; Yann Huey Ng; Yang Cao; Xiao Suo Wang; Yanchuang Han; Saki Tomita; Angela Yu Bai; Benjamin Hunter; Ashish Misra et al., 2025"

"Cardiac Substrate Utilization and Relationship to Invasive Exercise Hemodynamic Parameters in HFpEF, JACC. Basic to translational science, O'Sullivan JF; Li M; Koay YC; Wang XS; Guglielmi G; Marques FZ; Nanayakkara S; Mariani J; Slaughter E; Kaye DM, 2024"

"The first human normative ranges and biomarker performance of dimethylguanidino valeric acid isoforms in fatty liver disease, Pathology, Qadri S; Wang X; Tran C; Fitzpatrick M; Bonnitcha P; Sullivan D; Yki-Järvinen H; O'Sullivan JF, 2023"

"Destabilization of Atherosclerotic Plaque by Bilirubin Deficiency, Circulation Research, Weiyu Chen; Sergey Tumanov; Christopher P. Stanley; Stephanie M.Y. Kong; James Nadel; Niv Vigder; Darren L. Newington; Xiao Suo Wang; Louise L. Dunn; Roland Stocker, 2025"

Dmitry Guschin | Biological Networks |  Outstanding Research Achievement Award

Published on by Network Science

Dr. Dmitry Guschin | Biological Networks |  Outstanding Research Achievement Award

Sirius university of Science and Technology | Russia

Author Profiles

Oricd ID

Google Scholar

Early Academic Pursuits

Dr. Dmitry Guschin began his scientific journey in Moscow, Russia, where his early research as a Research Scientist at the Laboratory of Chromosome Structure (1990–1991) focused on the role of histone tails in maintaining chromatin structure during transcription. This pioneering work, published in Cell, laid the foundation for his long-term interest in chromatin dynamics and molecular mechanisms of gene regulation. His subsequent fellowship at the Imperial Cancer Research Fund in London (1991–1995) enabled him to uncover the role of Jak kinases in interferon signaling, a finding published in Nature. These formative years established his reputation as a molecular biologist with a keen ability to address fundamental questions in gene regulation.

Professional Endeavors

Throughout his career, Dr. Guschin has held prestigious positions across internationally recognized institutions. From visiting scientist roles at Argonne National Laboratory and the NIH, to his decade-long tenure at Sangamo BioSciences (2000–2014), he contributed to groundbreaking advances in genome editing. His later positions at the Institute of Basic Science in Korea (2015–2019), Moscow Institute of Physics and Technology (2019–2022), Ecole Polytechnique (2021), Nazarbaev University (2023–2024), and his current role as Lead Scientist at Sirius University (2024–) reflect a global career marked by innovation, collaboration, and leadership.

Contributions and Research Focus

Dr. Guschin’s research has consistently revolved around genome editing, chromatin biology, and translational medicine. At Sangamo BioSciences, he demonstrated targeted deletions using Zinc-Finger nucleases and developed methods for genome mutation detection, securing 10 U.S. patents. His contributions to CRISPR research at the Institute of Basic Science in Korea, where he engineered Cpf1 (CRISPR type V) proteins with novel PAM specificities, further advanced gene-editing precision. Additionally, his innovations in base editing and co-selection strategies positioned him as a thought leader in functional genomics.

Impact and Influence

The global trajectory of Dr. Guschin’s career underscores his broad scientific influence. His work has impacted both fundamental science-such as uncovering chromatin regulation mechanisms-and applied biotechnology, including methods adopted for therapeutic genome editing. His publications in Cell, Nature, Nature Biotechnology, and Science highlight the international recognition of his discoveries. Moreover, his patents and translational research contributions demonstrate lasting influence on both academia and industry.

Academic Citations

With over 20 peer-reviewed publications in top-tier journals, Dr. Guschin’s scholarship has been widely cited across molecular biology, biochemistry, and genome engineering fields. His publications not only advanced scientific discourse but also served as reference points for subsequent innovations in gene-editing technologies and cancer research.

Legacy and Future Contributions

Dr. Guschin’s legacy lies in bridging basic molecular discoveries with applied genome-editing technologies. His early contributions to chromatin biology and interferon signaling remain benchmarks in molecular biology, while his later work in Zinc-Finger nucleases and CRISPR engineering has influenced therapeutic development pipelines. In his current role at Sirius University, he continues to shape translational medicine by focusing on colloidal medicine and advanced biomedical applications. Looking forward, his expertise positions him to mentor future scientists and contribute to cutting-edge therapies in personalized medicine.

Conclusion

Dr. Dmitry Guschin’s career reflects a rare blend of scientific depth, technological innovation, and translational impact. From uncovering fundamental molecular mechanisms to pioneering genome-editing tools and mentoring the next generation, his contributions have left an indelible mark on modern biology. His ongoing work promises to expand the horizons of translational and personalized medicine, ensuring his influence will continue to grow in both academic and clinical domains.

Notable Publications

"Circulating Tumor DNA in Prostate Cancer: A Dual Perspective on Early Detection and Advanced Disease Management" 

  • Author: Stepan A. Kopytov; Guzel R. Sagitova; Dmitry Y. Guschin; Vera S. Egorova; Andrei V. Zvyagin; Alexey S. Rzhevskiy
  • Journal: Cancers
  • Year: 2025

"Modern approaches to engineering human reporter cell lines using CRISPR within Safe Harbor loci and endogenous genes" 

  • Author: A. G. Bykonya; D. Y. Guschin; N. A. Barlev
  • Journal: Critical Reviews in Biotechnology
  • Year: 2025

"Vinculin–Arp2/3 interaction inhibits branched actin assembly to control migration and proliferation" 

  • Author: John James; Artem I Fokin; Dmitry Y Guschin; Hong Wang; Anna Polesskaya; Svetlana N Rubtsova; Christophe Le Clainche; Pascal Silberzan; Alexis M Gautreau; Stéphane Romero
  • Journal: Life Science Alliance
  • Year: 2025

"BRCA Mutations-The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers" 

  • Author: Loboda, Anna P.; Adonin, Leonid S.; Zvereva, Svetlana D.; Guschin, Dmitri Y.; Korneenko, Tatyana V.; Telegina, Alexandra V.; Kondratieva, Olga K.; Frolova, Sofia E.; Pestov, Nikolay B.; Barlev, Nick A.
  • Journal: International Journal of Molecular Sciences
  • Year: 2023

"Vinculin-Arp2/3 Interaction Inhibits Branched Actin Assembly to Control Cell Migration and Cell Cycle Progression" 

  • Author: John James; Artem I. Fokin; Dmitry Y. Guschin; Hong Wang; Anna Polesskaya; Svetlana N. Rubtsova; Christophe Le Clainche; Pascal Silberzan; Alexis M. Gautreau; Stéphane Romero
  • Journal: Preprint
  • Year: 2023

 

 

Dimitrios G. Tsoukas | Biological Networks | Best Researcher Award

Published on by Network Science

Dr. Dimitrios G. Tsoukas | Biological Networks | Best Researcher Award

Mitera Hospital Athens | Greece

Author Profile

Scopus

Orcid ID

EARLY ACADEMIC PURSUITS

Dr. Dimitrios G. Tsoukas began his academic journey with exceptional distinction, graduating with a Bachelor in Medicine from the National and Kapodistrian University of Athens Faculty of Medicine. His early academic excellence set the foundation for a career rooted in clinical precision and innovative thinking. His education emphasized not only traditional orthopaedic surgery but also introduced him to minimally invasive techniques, which would later define his clinical signature.

PROFESSIONAL ENDEAVORS

Dr. Tsoukas's professional career spans over two decades of dynamic clinical and academic leadership. Currently, he serves as the Director of the E’ Orthopaedic Clinic for Advanced Arthroscopic Sports and Regenerative Surgery at MITERA Hospital (HH Group). He is also an Adjunct Professor at the University of Nebraska-Lincoln (USA) and has held numerous leadership positions at top hospitals across Greece and Cyprus. His pioneering efforts led to the founding of MIOSMED Center, an internationally recognized teaching hub endorsed by ISAKOS, ESSKA, and ICRS, and the Elite Regenerative Clinic Athens, a Lipogems SpA Center of Excellence. His clinical footprint spans not only orthopaedics but also women’s health, athletic injuries, and sports medicine innovation.

CONTRIBUTIONS AND RESEARCH FOCUS ON BIOLOGICAL NETWORKS

Dr. Tsoukas is a distinguished authority in arthroscopic, minimally invasive, and regenerative orthopaedic surgery, with special emphasis on adipose-derived stem cell applications for arthritis and joint degeneration. His contributions include advanced biological techniques in cartilage regeneration, joint preservation, and tendon repair. He has played a leading role in global education by serving as a certified instructor for ESSKA, contributing to simulation-based medical training, and mentoring young surgeons. His research interests include low-cost arthroscopy simulators, stem cell therapies, sports injury prevention in children, and medical device innovation.

IMPACT AND INFLUENCE

Dr. Tsoukas is recognized as a Key Opinion Leader (KOL) in orthopaedics and regenerative medicine, actively shaping clinical best practices and treatment protocols. His influence is reflected through editorial board memberships, reviewer roles for high-impact journals like the British Journal of Sports Medicine and the Orthopaedic Journal of Sports Medicine, and his participation in international regulatory and scientific committees. His appointment as a TEDx speaker in Kigali, Rwanda (2023) further underscores his role in global medical outreach and inspiration.

ACADEMIC CITES

As a scientific collaborator, Dr. Tsoukas has contributed to various institutions including the Athens University Medical School, Medical Physics Laboratory Simulation Center, and the European University of Cyprus. He has been involved in academic teaching, research, and publication, significantly advancing clinical education in Europe and the United States. He also served as Editor-in-Chief of the Journal of Stem Cell Research, and is a respected peer reviewer, ensuring academic rigor across multiple orthopaedic publications.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Dimitrios G. Tsoukas’s legacy is deeply embedded in medical innovation, education, and regenerative orthopaedics. As a fellow member of ICRS (2024) and an American Board of Regenerative Medicine Diplomat, he continues to push the boundaries of biological orthopaedic science. His ongoing leadership in global campaigns like “STOP Sports Injuries in Children” and collaborative research with biotechnology leaders like Terumo BCT, Arthrex, and Lipogems positions him as a visionary in the future of personalized, minimally invasive care. His legacy will endure through the institutions he built, the surgeons he trained, and the global initiatives he leads.

HONORS AND RECOGNITIONS

Dr. Tsoukas has received numerous accolades recognizing his contributions to orthopaedic science and Greek athletics. Among these are the Silver Award for Surgical Innovation at the Boussias Healthcare Business Awards 2021, the Med Professionals Honor for Stem Cell Innovation (2022), and several sports awards acknowledging his contributions to Greek basketball and volleyball. He holds the rare distinction of being enlisted in the Guinness World Records for medical contributions to the record-setting Athinaikos female basketball team.

OTHER SIGNIFICANT AFFILIATIONS AND LICENSES

Dr. Tsoukas maintains international medical licensure in Switzerland and Dubai, and continues to collaborate with organizations such as ECOSEP, CEV, and Smith & Nephew’s European Knee Advisory Board. These affiliations highlight his global reach and his role in shaping orthopaedic protocols across continents. His role as Head Doctor for National and Professional Teams underscores his credibility and trust within elite athletic circles.

NOTABLE PUBLICATIONS

"Prospective Observational Study of a Non-Arthroscopic Autologous Cartilage Micrografting Technology for Knee Osteoarthritis" 

  • Author: Dimitrios Tsoukas; Ilie Muntean; Christos Simos; Ruben Sabido-Vera
  • Journal: Bioengineering
  • Year: 2023